The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) plays important roles in tumor development and progression. Among many functions, PTEN negatively regulates the AKT anti-apoptotic signaling pathway, while nuclear PTEN affects the cell cycle by repressing the mitogen-activated protein kinase pathway. However, the regulation of PTEN expression is still not well understood. We previously reported that androgen receptor (AR) activates PTEN transcription in breast cancer cells. Here, we found that the transcription factor GATA2 (GATA binding protein 2) is overexpressed in non-cultured human breast carcinomas and is negatively correlated with PTEN expression. We then showed GATA2 promotes breast cancer cell growth and stimulates AKT phosphorylation by inhibiting PTEN transcription. We mapped a GATA2-binding site in the PTEN promoter, whereby GATA2 not only blocks AR-induced PTEN expression by preventing AR nuclear translocation, but also directly represses PTEN transcription independent of AR. Most importantly, for the first time, we have discovered a novel reverse regulation within the traditional PTEN/AKT signaling pathway, whereby AKT induces GATA2 with consequent decreased PTEN transcription, likely germane in tumor invasion and metastases but not initiation.
INTRODUCTION
The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) is one of the most frequently mutated or deleted genes in inherited and sporadic human cancers, including breast carcinomas (1) . Through its phospholipid 3-phosphatase activity, PTEN negatively regulates the PI3K/Akt signaling pathway, which is crucially involved in cell proliferation, migration and apoptosis. As a result of decreased PTEN, AKT phosphorylation and activity are significantly increased in a broad range of cancer cells causing the increased cell proliferation. Although it has been intensely studied, the mechanism of how PTEN is regulated during tumor development, progression and metastasis remains unclear.
The androgen receptor (AR), a member of the nuclear receptor superfamily, regulates its target genes through specific androgen response elements (ARE) in promoter regions. Expression of AR in patients' breast tumors has been reported to be significantly associated with increased survival and good prognosis (2, 3) . We have previously shown that AR is positively correlated with PTEN expression in breast carcinomas, which is due to the direct activation of PTEN transcription, mediated by an ARE site in the PTEN promoter (4) . GATA2 (GATA binding protein 2) belongs to the family of GATA transcription factors, which is expressed in a diverse set of tissues and has been shown to play essential roles in hematopoietic, adipocyte and pituitary development (5 -7). GATA2-binding motifs are significantly enriched within AR-binding regions throughout the human genome, suggesting a functional correlation between AR and GATA2 (8) . A recent study showed that GATA2 regulates AR-target gene expression by acting as an AR cofactor in prostate cancer cells, suggesting * To whom correspondence should be addressed at: Cleveland Clinic Genomic Medicine Institute, 9500 Euclid Avenue, NE-50, Cleveland, OH 44195, USA. Tel: +1 2164443440; Fax: +1 2166360655; Email: engc@ccf.org # The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
its role in tumorigenesis (9) . While it is logical to study AR/ GATA2 signaling in male-relevant malignancies, so far, GATA2 and its function have never been studied in female malignancies. Because of the newly emerging observations that traditional male hormonal signaling pathways may be relevant, but completely different, in female cancers (4), we hypothesize that GATA2, as an AKT downstream target, can repress PTEN expression via multiple AR-dependent and -independent pathways in a prototype female malignancy, breast cancer.
RESULTS

GATA2 is overexpressed in patient breast carcinomas, and stimulates cancer cell growth
Increased GATA2 protein expression has been reported to be associated with biochemical recurrence and distant metastatic progression in prostate cancer (9) . To begin to explore its role in our prototype female malignancy, breast carcinoma and to determine patient-relevance, we first performed in silico comparisons of GATA2 and PTEN expression between normal breast and breast cancer tissues using publicly available whole genome transcriptome data sets utilizing non-cultured breast carcinomas derived from patients. A search through the Gene Expression Omnibus was performed to identify published studies that analyze normal breast tissue and ductal carcinoma in situ (DCIS), invasive and metastatic breast carcinomas from patients not exposed to any treatment. By these criteria, 779 tissue samples were finally identified for this analysis. Box and whisker plots showed that GATA2 expression is significantly increased in breast carcinomas, especially metastatic tumors, compared with normal breast tissues (Fig. 1A, left panel) . In contrast, PTEN expression is decreased in breast carcinomas compared with normal breast tissue, while the metastatic tumors express much less PTEN than the primary tumors (Fig. 1A, right panel) . Next, we examined whether the expression of GATA2 and PTEN are correlated in breast carcinoma tissues. This Forest plot showed a negative correlation between GATA2 and PTEN transcript expression in breast cancer tissues (correlation coefficient 20.11, 95% CI: 20.18 to 20.04; Fig. 1B ). From these correlative data, we postulated that GATA2 is upregulated in breast carcinomas and might negatively influence PTEN expression at the transcriptional level (or vice versa).
In order to further elucidate the role that GATA2 plays in breast carcinogenesis, we surveyed GATA2 protein expression in several breast cancer cell lines. MDA-MB-453, MCF-7 and BT20 cells express high levels of GATA2 protein compared with other breast cancer lines (Fig. 1C) . Immunostaining clearly showed GATA2 nuclear localization, representing activated GATA2 as a functional transcription factor in breast cancer cells (Supplementary Material, Fig. S1 ). Next, we used the MTT assay to determine GATA2's effect on cell growth. After overexpressing GATA2, we found increased proliferation, accompanied by increased S-phase fraction in breast cancer cells (Fig. 1D and Supplementary Material, Fig. S2 ), while GATA2 knockdown inhibited cell growth (Supplementary Material, Fig. S3A ). This GATA2-stimulated cell growth is most likely independent of p53, as it was observed in MCF-7 (p53 wild-type), MDA-MB-453 (p53 null) and MDA-MB-231 (p53 mutation) cells. In vitro migration assay revealed that breast cancer cells achieved increased migration ability after GATA2 overexpression, while GATA2 knockdown inhibited cell migration ( Fig. 1E and Supplementary Material, Fig. S3B ). Therefore, our data suggest that upregulated GATA2 in breast carcinoma cells provides these cells with an advantage in proliferation and migration, with implications for progression and metastasis.
GATA2 inhibits PTEN expression by direct transcriptional control in breast cancer cells
Our in silico data above indicate that GATA2 expression is inversely correlated with PTEN expression in human breast cancer ( Fig. 1A and B) . In order to investigate the mechanism of GATA2's role in promoting breast cancer growth, we hypothesized that GATA2 directly or indirectly represses PTEN expression and regulates its downstream AKT pathways in breast cancer cells. Corroborating the correlative data from human breast cancer samples ( Fig. 1A and B) , western blots showed that ectopic overexpression of GATA2 resulted in decreased PTEN protein levels and upregulated AKT phosphorylation in both MDA-MB-453 and MCF-7 cells ( Fig. 2A and Supplementary Material, Fig. S4A ). This change in AKT phosphorylation was not observed in PTEN null MDA-MB-468 cells, suggesting that GATA2-regulated AKT phosphorylation is mediated by PTEN inhibition ( Fig. 2A) . The quantitative reverse transcription-polymerase chain reaction (qRT -PCR) shows that GATA2 expression decreased endogenous PTEN mRNA by more than half, while GATA2 knockdown by siRNA increased PTEN mRNA levels by almost 2-fold, indicating that GATA2-mediated downregulation of PTEN expression is mediated by transcriptional repression (Fig. 2B) . Conversely, siRNA-induced GATA2 knockdown resulted in corresponding PTEN protein upregulation (Fig. 2B) .
Next, we used the chromatin immunoprecipitation (ChIP) assay to investigate whether GATA2 can directly bind to the PTEN promoter in order to repress its transcription. Our ChIP assay clearly showed an interaction between GATA2 and the PTEN promoter in MDA-MB-453 and MCF-7 cells ( Fig. 2C and Supplementary Material, Fig. S4B ). Based on GATA2's conserved binding sequence xGATAx, we projected two potential GATA2-binding domains at 21219 and at 2879 of the PTEN promoter (Fig. 2D, upper panel) . In order to precisely identify the GATA2 response elements, we made a series of luciferase reporter constructs, driven by PTEN promoters containing deletion or substitution mutations at the predicted GATA2-binding domains. Breast cancer cells were transfected with each of the mutant PTEN promoterreporter constructs or the wild-type as control (Fig. 2D ). Overexpression of GATA2 significantly repressed wild-type PTEN promoter activity and the deletion/substitution mutations at the 21219 site did not affect this inhibitory effect (Fig. 2D , lower panel). In contrast, the deletion or substitution mutations at 2879 totally abolished GATA2's repressive effect on the PTEN promoter ( Fig. 2D and Supplementary Material, Fig. S5 ). These data mechanistically explain the inverse correlation between GATA2 and PTEN expression in the patient breast carcinoma samples.
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GATA2 inhibits AR-induced PTEN expression by preventing nuclear translocation of AR
GATA2 has been reported as an AR co-factor for regulating gene expression and we revealed that the AR -PTEN correlation in breast cancer is due to the direct activation of PTEN transcription by AR, mediated by an ARE site in the PTEN promoter (4, 8) . Dihydrotestosterone (DHT), a steroid hormone that activates AR, increased PTEN expression and inhibited AKT phosphorylation in MDA-MB-453 cells (Fig. 3A) . Overexpression of GATA2 not only decreased PTEN protein levels, but also prevented the expected DHT-induced PTEN expression Human Molecular Genetics, 2012, Vol. 21, No. 3 571 (Fig. 3A) . Next, we transfected MDA-MB-453 cells with a luciferase reporter driven by the PTEN promoter, containing both AR-and GATA2-binding sites. GATA2 overexpression not only repressed the PTEN promoter but also abolished DHT-induced PTEN promoter activity (Fig. 3B ). GATA2 knockdown relieved the PTEN promoter from this inhibitory effect (Fig. 3B) . To further investigate the mechanism of how GATA2 antagonizes AR-induced PTEN transcription, we overexpressed GATA2 in MCF-7 and MDA-MB-453 cells. ChIP assays showed that GATA2 could prevent the interaction between AR and the PTEN promoter (Fig. 3C) . After subcellular fractionation, we found that GATA2 blocks AR nuclear localization (Fig. 3D) . Therefore, our data suggest that GATA2 prevents AR from translocating to the nucleus and binding to the PTEN promoter, resulting in inhibition of PTEN transcription.
GATA2 also inhibits PTEN expression through an AR-independent mechanism
In order to determine whether AR is the sole mediator of GATA2's effect on PTEN expression, we transfected PTEN promoter -reporter and GATA2 constructs into AR-null (MDA-MB-231 and MDA-MB-468) as well as AR-positive (MCF7 and MDA-MB-453) cell lines (Fig. 3E) . Interestingly, we found that GATA2 repressed PTEN promoter activity in all cell lines, suggesting that GATA2 can also repress PTEN expression through an AR-independent mechanism (Fig. 3E) . Next, we expressed GATA2 in AR-negative breast cancer cells to confirm this AR-independent GATA2 effect on endogenous PTEN expression. Western blots showed that GATA2 overexpression resulted in a decreased PTEN protein level and increased phospho-AKT in MDA-MB-231 and AU565 cells (Fig. 3F and Supplementary Material, Fig. S7A ). Furthermore, we used anti-AR siRNA to knock down AR in MDA-MB-453 cells, which resulted in decreased PTEN mRNA levels (Fig. 3G ). We were able to observe that GATA2 could still inhibit endogenous PTEN expression even after AR knockdown (Fig. 3G ). Thus far, we conclude that GATA2 not only blocks AR-induced PTEN transcription in AR-positive breast cancer cells, but also directly inhibits PTEN transcription as a transcription repressor, independent of AR, in AR-negative cells. 
AKT inhibits PTEN expression through increased GATA2
Resveratrol is a phytoalexin, commonly exists in a wide variety of fruits (10) . Our previous studies revealed that resveratrol exposure increases PTEN protein levels in breast cancer cells (11) . We also reported that resveratrol could inhibit EGFR activity and decreases AKT phosphorylation (12, 13) . To investigate the mechanism in which resveratrol increases PTEN expression, we first used resveratrol to inhibit AKT phosphorylation in MDA-MB-453 cells (Fig. 4A) . Surprisingly, GATA2 protein levels decreased after the treatment and resulted in upregulated PTEN expression (Fig. 4A) . In contrast, in GATA2-negative MDA-MB-231 and AU565 cell lines, PTEN protein levels were not affected by resveratrol-induced AKT dephosphorylation (Fig. 4A , right panel and Supplementary Material, Fig.  S7B ). Based on these data, we hypothesized that AKT stimulates GATA2 expression, and downregulates PTEN protein levels in breast cancer cells. In order to confirm our hypothesis, we expressed a constitutively activated AKT (myr-AKT) (14) in both GATA2-positive and -negative breast cancer cells. An earlier study reported that AKT phosphorylates GATA2 and stimulates its transcriptional activity in adipocytes (7) . Here, we found that AKT hyper-activation induced a significant increase in GATA2 protein levels in GATA2-positive cells, and, as a result, PTEN expression was significantly decreased (Fig. 4B) . PTEN protein levels did not show any decrease in GATA2-null MDA-MB-231 and AU565 cells after activation of AKT (Fig. 4B and Supplementary Material, Fig. S7C ). qRT -PCR showed that myr-AKT stimulated GATA2 mRNA expression and resulted in a 50% decrease in endogenous PTEN mRNA levels (Fig. 4C) . p53 has been shown as a positive regulator of PTEN expression (15) . In order to determine whether p53 could rescue AKT-induced PTEN repression, we overexpressed both p53 and myr-AKT in MCF-7 and MDA-MB-453 cells (Fig. 4D) . Myr-AKT decreased PTEN levels in both cell lines, while additional expression of p53 overcame this effect (Fig. 4D) . Therefore, we conclude from these data that activation of AKT can inhibit PTEN expression at the transcriptional level by upregulating GATA2, at least in breast cancer cells.
DISCUSSION
PTEN is one of the most important and widely studied tumor suppressor genes in human cancers. To date, little is known about the regulation of PTEN expression, especially that mediated by its downstream cell signaling transduction pathways. Here, we demonstrate a novel feedback loop in breast carcinogenesis, whereby AKT and PTEN negatively regulate each other. This feedback is mediated by GATA2, which suppresses PTEN transcription in an AR-dependent and -independent manner (Fig. 4E) . Therefore, our study elucidates the mechanism behind our observation of increased GATA2 expression correlating with decreased PTEN expression in non-cultured patient breast cancer samples.
Other GATA family members unrelated to sex steroid hormone signaling, such as GATA1 and GATA3, have been reported to play different roles in breast carcinogenesis (16, 17) . GATA2, as a transcription factor, is well studied in hematopoietic development in the past decade. Recent publications started to reveal its role in tumorigenesis. In prostate cancer cells, for example, GATA2 is directly recruited to the promoter with the AR and contributes to progression to aggressive prostate cancer through modulation of expression of AR and key androgen-regulated genes (9) . This GATA2-induced AR expression was not observed in breast cancer cells (Fig. 2A) . Instead, we found that GATA2 inhibited AR nuclear translocation and hence, prevented AR's physical interaction with the PTEN promoter. Interestingly, we also found that a GATA2 del ZF mutation (with deleted zinc finger domains) had no effect on PTEN transcription nor AR nuclear localization, suggesting its DNA-binding ability is crucial for GATA2-mediated downregulation of PTEN transcription (Supplementary Material, Fig. S6 ).
To date, there exists only one publication reporting GATA2 expression in non-cultured breast carcinomas (18) . This single study (comprising 59 tumor and 17 control tissues) showed that breast carcinomas have decreased GATA2 expression when compared with normal tissue, but also showed that the metastatic tumors had much higher GATA2 levels when compared with their primary tumors (18) . The difference between 
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Human Molecular Genetics, 2012, Vol. 21, No. 3 our study and this previous report may be due to sample size and the different sample selection criteria. First, we only chose data sets that had .100 patients. Secondly, we specifically excluded cultured cancer cells and any patients who received prior/ on-going treatment. Consistent with the previous report, however, we also found that recurrent/metastatic breast cancers express particularly high levels of GATA2 and low levels of PTEN compared with primary breast cancers. Furthermore, GSE26304 (Fig. 1B) , our only data set that did not show the inverse correlation between GATA2 and PTEN expression, comprised DCIS and very early invasive breast cancers. Conversely, GSE26338 is the data set with the most metastatic samples, repenting the largest inverse correlation between GATA2/PTEN expressions. These observations in patient samples and our in vitro data together suggest that GATA2 is a key mediator involved in breast cancer invasion, tumor progression and metastasis, but not transformation. Interestingly, those patients in our selected data sets who received chemotherapy had decreased GATA2 expression in the tumors (data not shown), indicating that GATA2 could be both a marker to follow treatment as well as a potential therapeutic target. An earlier study suggested that AKT is able to directly phosphorylate GATA2, resulting in increased GATA2 nuclear translocation and transcriptional activity in adipocytes (7) . In breast cancer cells, inhibiting AKT activity by resveratrol, LY294002 or wortmannin resulted in decreased GATA2 protein levels ( Fig. 4A and Supplementary Material, Fig. S8A and C) . Conversely, constitutively activated AKT dramatically stimulates GATA2 expression at the transcriptional level in breast cancer cells. This GATA2 upregulation is most likely mediated by AKT downstream mammalian target of rapamycin (mTOR) pathway signaling, as mTOR inhibitor rapamycin abolished AKT-induced GATA2 expression (Supplementary Material, Fig. S8B ).
In summary, our study shows that the PI3K-PTEN-AKT signal transduction pathway is a complicated network, containing multiple levels of feedback. These feedback loops now involve nuclear hormone receptor pathways, such as that of AR, which associates with increased survival and good prognosis among breast cancer patients. For the first time, we show that AKT could repress PTEN expression, forming a negative feedback in this pathway. This feedback is mediated by GATA2, which is overexpressed in breast carcinomas, resulting in repression of PTEN transcription via several mechanisms and stimulation of AKT phosphorylation, providing tumor cell advantage mainly for proliferation, invasion and metastasis, but not necessarily initiation/initial transformation. Therefore, our observations here provide a potential new target for therapy and drug development for breast cancer. It also poses the challenge to determine the pre-GATA2 initiation mechanism for tumorigenesis.
MATERIALS AND METHODS
Statistical analysis of GATA2 and PTEN in breast carcinomas
The significance of GATA2 and PTEN expression among different groups was calculated by one-way analysis of variance.
The bottom and top of the box represent the lower and upper quartiles, respectively. Meta-analysis of the correlation coefficient between GATA2 and PTEN was performed in R version 2.10.0 (19) . Forest plots summarize estimates of the correlation between the expression of PTEN and GATA2 in breast cancer tumor tissues.
Cell culture and treatments
Breast cancer cell lines: MDA-MB-231, MDA-MB-453, MDA-MB-468, MCF-7, BT-474, HCC1395, BT20, MDA-MB-436, SKBR3 and AU565 cells were purchased from the ATCC (American Type Culture Collection, Manassas, VA, USA). Cells were cultured in 'compete-medium' per ATCC recommendation, with 10% fetal bovine serum (FBS). DHT is from Steraloids (Newport, RI, USA). LY294002 is from Calbiochem (La Jolla, CA, USA). Resveratrol is from Sigma-Aldrich (St Louis, MO, USA). Control siRNA was a pool of four-scrambled non-specific siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-AR and anti-GATA2 siRNA are from ThermoFisher scientific (Pittsburgh, PA, USA).
Western blotting
Western blotting was performed as described elsewhere (20) . Mouse monoclonal anti-AR is from Santa Cruz Biotechnology. Mouse monoclonal anti-tubulin antibody is from Sigma-Aldrich. Mouse monoclonal anti-PTEN antibody is from Cascade Biosciences (Portland, OR, USA). Rabbit polyclonal anti-phospho-AKT (Ser473), anti-total AKT, anti-GATA2 and anti-Lamin A antibodies are from Cell Signaling Technology (Beverly, MA, USA).
Promoter activity assay
We generated PTEN promoters tagged with the firefly luciferase gene as described in our previous study (21) . Reporter gene activity was determined by the dual luciferase assay using a luciferase enzyme assay system (Promega Corp., Madison, WI, USA).
In vitro migration assay
Migration assays were performed with the QCM Colorimetric Cell Migration Assay kit according to the manufacturer's protocol (Millipore, Billerica, MA, USA). A total of 100 000 cells, transfected with control vector or GATA2, were seeded in 24-well filter-inserts, and allowed to migrate toward 10% FBS for 8 h. Colorimetric measurements were taken according to assay instructions.
Quantitative reverse transcription-polymerase chain reaction (qRT -PCR)
qRT -PCR to quantitate PTEN mRNA expression was measured as described previously (4), using SYBR Green (Applied Biosystem, Foster City, CA, USA). Expression of GAPDH was used as the internal control. PTEN primers are as following: F: AAAGGCACAAGAGGCCCTAGAT. R: CAAGTTCCGCCACTGAACATTGGAA.
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